Cost-effectiveness of introducing national seasonal influenza vaccination for adults aged 60 years and above in mainland China: a modelling analysis.
China
Cost-effectiveness analysis
Influenza
Older adults
Vaccination
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
14 04 2020
14 04 2020
Historique:
received:
04
12
2019
accepted:
03
03
2020
entrez:
15
4
2020
pubmed:
15
4
2020
medline:
17
12
2020
Statut:
epublish
Résumé
China has an aging population with an increasing number of adults aged ≥ 60 years. Influenza causes a heavy disease burden in older adults, but can be alleviated by vaccination. We assessed the cost-effectiveness of a potential government-funded seasonal influenza vaccination program in older adults in China. We characterized the health and economic impact of a fully funded influenza vaccination program for older adults using China-specific influenza disease burden, and related cost data, etc. Using a decision tree model, we calculated the incremental costs per quality-adjusted life year (QALY) gained of vaccination from the societal perspective, at a willingness-to-pay threshold equivalent to GDP per capita (US$8840). Moreover, we estimated the threshold vaccination costs, under which the fully funded vaccination program is cost-effective using GDP per capita as the willingness-to-pay threshold. Compared to current self-paid vaccination, a fully funded vaccination program is expected to prevent 19,812 (95% uncertainty interval, 7150-35,783) influenza-like-illness outpatient consultations per year, 9418 (3386-17,068) severe acute respiratory infection hospitalizations per year, and 8800 (5300-11,667) respiratory excess deaths due to influenza per year, and gain 70,212 (42,106-93,635) QALYs per year. Nationally, the incremental costs per QALY gained of the vaccination program is US$4832 (3460-8307), with a 98% probability of being cost-effective. The threshold vaccination cost is US$10.19 (6.08-13.65). However, variations exist between geographical regions, with Northeast and Central China having lower probabilities of cost-effectiveness. Our results support the implementation of a government fully funded older adult vaccination program in China. The regional analysis provides results across settings that may be relevant to other countries with similar disease burden and economic status, especially for low- and middle-income countries where such analysis is limited.
Sections du résumé
BACKGROUND
China has an aging population with an increasing number of adults aged ≥ 60 years. Influenza causes a heavy disease burden in older adults, but can be alleviated by vaccination. We assessed the cost-effectiveness of a potential government-funded seasonal influenza vaccination program in older adults in China.
METHODS
We characterized the health and economic impact of a fully funded influenza vaccination program for older adults using China-specific influenza disease burden, and related cost data, etc. Using a decision tree model, we calculated the incremental costs per quality-adjusted life year (QALY) gained of vaccination from the societal perspective, at a willingness-to-pay threshold equivalent to GDP per capita (US$8840). Moreover, we estimated the threshold vaccination costs, under which the fully funded vaccination program is cost-effective using GDP per capita as the willingness-to-pay threshold.
RESULTS
Compared to current self-paid vaccination, a fully funded vaccination program is expected to prevent 19,812 (95% uncertainty interval, 7150-35,783) influenza-like-illness outpatient consultations per year, 9418 (3386-17,068) severe acute respiratory infection hospitalizations per year, and 8800 (5300-11,667) respiratory excess deaths due to influenza per year, and gain 70,212 (42,106-93,635) QALYs per year. Nationally, the incremental costs per QALY gained of the vaccination program is US$4832 (3460-8307), with a 98% probability of being cost-effective. The threshold vaccination cost is US$10.19 (6.08-13.65). However, variations exist between geographical regions, with Northeast and Central China having lower probabilities of cost-effectiveness.
CONCLUSIONS
Our results support the implementation of a government fully funded older adult vaccination program in China. The regional analysis provides results across settings that may be relevant to other countries with similar disease burden and economic status, especially for low- and middle-income countries where such analysis is limited.
Identifiants
pubmed: 32284056
doi: 10.1186/s12916-020-01545-6
pii: 10.1186/s12916-020-01545-6
pmc: PMC7155276
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Subventions
Organisme : National Science Fund for Distinguished Young Scholars
ID : 81525023
Pays : International
Organisme : National Natural Science Foundation of China
ID : 81903373
Pays : International
Organisme : National Institute for Health Research
ID : 16/137/109
Pays : International
Références
BMJ Glob Health. 2018 Nov 5;3(6):e000964
pubmed: 30483412
Vaccine. 2013 Nov 4;31(46):5339-48
pubmed: 24055351
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
BMJ Open. 2019 Jan 25;9(1):e024080
pubmed: 30782725
BMC Infect Dis. 2017 Oct 16;17(1):686
pubmed: 29037172
Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Oct 6;53(10):993-999
pubmed: 31607044
PLoS One. 2013 Sep 09;8(9):e73724
pubmed: 24040041
Lancet Infect Dis. 2014 Dec;14(12):1228-39
pubmed: 25455990
Emerg Infect Dis. 2018 Nov;24(11):2098-2102
pubmed: 30334719
Vaccine. 2016 Apr 19;34(18):2135-40
pubmed: 26917011
Vaccine. 2020 Jan 29;38(5):1057-1064
pubmed: 31787414
Int J Epidemiol. 2014 Feb;43(1):61-8
pubmed: 23243115
Vaccine. 2015 Jan 29;33(5):742-7
pubmed: 25454853
BMJ. 2016 Mar 24;352:i1750
pubmed: 27013557
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
Lancet Public Health. 2019 Sep;4(9):e473-e481
pubmed: 31493844
Vaccine. 2019 Jun 6;37(26):3419-3425
pubmed: 31097351
Vaccine. 2016 Apr 29;34(20):2329-33
pubmed: 27026147
Bull World Health Organ. 2012 Apr 1;90(4):279-288B
pubmed: 22511824
Hum Vaccin Immunother. 2017 Jan 2;13(1):103-110
pubmed: 27690757
Vaccine. 2017 May 25;35(23):3129-3134
pubmed: 28456530
BMC Infect Dis. 2018 Oct 4;18(1):502
pubmed: 30286735
Vaccine. 2016 Nov 11;34(47):5724-5735
pubmed: 27745951
Influenza Other Respir Viruses. 2014 Jan;8(1):53-65
pubmed: 24209711
Infect Dis Poverty. 2015 Oct 06;4:44
pubmed: 26445412
J Health Econ. 1995 Jun;14(2):171-89
pubmed: 10154656
BMJ. 2013 Aug 23;347:f5061
pubmed: 23974637
Popul Stud (Camb). 2014;68(3):305-20
pubmed: 25098961
Euro Surveill. 2018 Jan;23(2):
pubmed: 29338809
PLoS Med. 2013 Nov;10(11):e1001552
pubmed: 24348203
Influenza Other Respir Viruses. 2013 Nov;7(6):1350-60
pubmed: 23668477